Jonathan A Coleman
Overview
Explore the profile of Jonathan A Coleman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
195
Citations
5359
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dawidek M, Calderon L, Arroyave Villada J, Ucpinar B, Eismann L, Reese S, et al.
Urol Pract
. 2025 Mar;
:101097UPJ0000000000000802.
PMID: 40084969
Purpose: While partial nephrectomy remains the preferred treatment for tumors in solitary kidneys, there is a broad range of complexity to these cases. This retrospective study refines our understanding of...
2.
Mittal A, Martin M, Levin E, Adams C, Yang M, Provins L, et al.
Nat Struct Mol Biol
. 2025 Mar;
PMID: 40050463
No abstract available.
3.
Wieteska L, Taylor A, Punch E, Coleman J, Conway I, Lin Y, et al.
Nat Commun
. 2025 Feb;
16(1):1778.
PMID: 40011426
Betaglycan (BG) is a transmembrane co-receptor of the transforming growth factor-β (TGF-β) family of signaling ligands. It is essential for embryonic development, tissue homeostasis and fertility in adults. It functions...
4.
Dawidek M, Arroyave Villada J, Vazquez-Rivera K, Fuchs H, Calderon L, Eismann L, et al.
Urol Pract
. 2025 Jan;
12(2):274-280.
PMID: 39874471
Introduction: This retrospective study furthers our understanding of risk factors associated with hemorrhage and intervention in renal angiomyolipomas (R-AMLs), particularly in larger tumors (≥4 cm) and in childbearing-age (CBA; younger...
5.
Kim K, Alam S, Kuo F, Chen Z, Yip W, Katims A, et al.
Eur Urol
. 2024 Nov;
87(3):342-354.
PMID: 39550333
Background And Objective: Molecular classification of upper tract urothelial carcinoma (UTUC) can provide insight into divergent clinical outcomes and provide a biological rationale for clinical decision-making. As such, we performed...
6.
Wieteska L, Taylor A, Punch E, Coleman J, Conway I, Lin Y, et al.
bioRxiv
. 2024 Aug;
PMID: 39091787
Betaglycan (BG) is a transmembrane co-receptor of the transforming growth factor-β (TGF-β) family of signaling ligands. It is essential for embryonic development and tissue homeostasis and fertility in adults. It...
7.
Chandran E, Iannantuono G, Atiq S, Akbulut D, Sinaii N, Simon N, et al.
BMJ Oncol
. 2024 Aug;
3(1).
PMID: 39086924
Background: Mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) occur in a subset of cancers and have been shown to confer sensitivity to immune checkpoint inhibition (ICI); however, there is...
8.
Budhu S, Kim K, Yip W, La Rosa S, Jebiwott S, Cai L, et al.
Front Oncol
. 2024 Jul;
14:1405486.
PMID: 38957315
Introduction: Immunotherapy is revolutionizing the management of multiple cancer types. However, only a subset of patients responds to immunotherapy. One mechanism of resistance is the absence of immune infiltrates within...
9.
George A, Miocinovic R, Patel A, Lomas D, Correa A, Chen D, et al.
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927884
The PRESERVE study (NCT04972097) aims to evaluate the safety and effectiveness of the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer (PCa). The NanoKnife uses irreversible...
10.
Eismann L, Zucker M, Dawidek M, Reese S, Calderon L, Aulitzky A, et al.
Urol Pract
. 2024 Jun;
11(5):860-870.
PMID: 38913557
Introduction: Oncological outcomes in patients with nonclear cell renal cell carcinoma (non-ccRCC) treated with surgery for locoregional nodal disease (ND) remain incompletely characterized. The objective was to investigate the characteristics...